Pasithea Therapeutics Corp. Stock News

Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tues

Pasithea Therapeutics (NASDAQ: KTTA ) stock is rocketing higher on Monday after the biotechnology company announced results from two preclinical trials of PAS-004. The first study saw positive results

-- Attendees may request 1 x 1 meeting with management at [email protected] --  PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“

                                      Pasithea Therapeutics Acquires AlloMek Therapeutics   -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor   -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023   -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Typ...

    Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis   -- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM -- -- PAS002 effectively reduces disease severity, delays onset of illness, while also reducing relapse severity -- -- GlialCAM fragment is present in MonkeyPox virus, supporting a potential role in current vaccine developm...

 Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC- Alpha-5 is a potentially First-In-Class monoclonal antibody for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth - - Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction - Miami Beach, FL -- June 22, 2022 -- InvestorsHub News...

  Pasithea Therapeutics Announces Collaboration with The Glimpse Group   - The Glimpse Group is a Virtual Reality and Augmented Reality platform company - Partnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders   Miami Beach, FL / March 8, 2022 -- InvestorsHub NewsWire -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel biotechnology company focused on...

Photo by Sydney Sims on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Mental health and substance abuse disorders are reportedly on the rise around the world, and healthcare providers are discovering alternatives to traditional medications to treat them, including psychedelics and ketamine. About 970 million people globally have mental health or substance abuse disorders; and 3.6% of the world’s population suffers from depression, according to Statista . Among the companies that have found ketamine — traditionally used as anesthesia — to be effective is Pasithea Therapeutics Corp. (NASDAQ: KTTA ). Pasithea provides ketamine treatments to patients grappling with mental health disorders. First approved by the U.S. Food and Drug Administration in 1970 as an anesthetic, ketamine has recently been repurposed for treating anxiety, depression, and PTSD. When taken in lower doses than used for anesthesia, ketamine …

Image by Christina on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Pasithea Therapeutics Corp. (NASDAQ: KTTA ) announced that its wholly-owned subsidiary, Pasithea Clinics, has expanded its treatment offer and is planning to open three new clinics in London to treat patients suffering from mental health issues. The Company already has locations in Marylebone and Knightsbridge. “With these new clinics, we will broaden our London footprint and start offering pharmacy services and new treatment options, bringing important and novel mental health therapies to an ever-growing number of people. In addition to pharmacy services, our London clinics will offer other psychiatric treatment therapies, including repeated transcranial magnetic stimulation in addition to intravenous (“IV”) ketamine” stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics. “With our strong cash … Full story available on Benzinga.

 Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022 -- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue ---- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial magnetic stimulation ("rTMS") -- Miami Beach, FL / January 24, 2022 -- InvestorsHub NewsWire -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a n...

Pasithea Therapeutics Corp. (NASDAQ:KTTA)’s traded shares stood at 1.3 million during the last session. At the last check today, the stock’s price was $1.27, to imply an increase of 5.14% or $0.06 in intraday trading. The KTTA share’s 52-week high remains $8.50, putting it -569.29% down since that peak but still an impressive 20.47% since … Pasithea Therapeutics Corp. (NASDAQ: KTTA) Stock Dropped -18.79% Over A Month – Any Room To Run? Read More »

PALM BEACH, Fla. , Feb. 3, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination, inflammation, and degenerative changes such as progressive brain and spinal cord atrophy, neuroaxonal loss, and others. According to the Multiple Sclerosis Trust, 2.5 million people in the world were estimated to have MS in 2017. In addition to this, the treatment cost of MS has become an economic burden in many countries. According to the Institute for Clinical and Economic Review, the annual cost of treatment in the U.S. is estimated to be USD 28,000.0 million . Hence, there is active government support for the treatment in terms of better healthcare spending, expert recommendations, and drug approvals. A report from Fortune Business Insights, projected that the global multiple sclerosis drugs market size was USD 26.05 billion in 2020. It continued: "The global impact of the COVID-19 has been unprecedented and staggering, with multiple sclerosis drugs witnessing a moderate negative demand shock across all regions amid the pandemic.

Pasithea Therapeutics Corp (KTTA) shares closed today at 0.7% above its 52 week low of $1.38, giving the company a market cap of $18M. The stock is currently down 21.5% year-to-date, down 61.0% over the past 12 months, and down 61.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 94.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8831.1% The company's stock price performance over the past 12 months lags the peer average by 284.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Making a penny stocks watchlist for January? Check these three out The post Hot Penny Stocks For Your January 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS

Pasithea Therapeutics Corp (KTTA) shares closed today 36.7% higher than it did at the end of yesterday. The stock is currently down 43.5% year-to-date, down 43.5% over the past 12 months, and down 43.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $2.38 and as low as $1.39 this week.Shares closed 76.4% below its 52-week high and 44.6% above its 52-week low.Trading volume this week was 85.4% lower than the 10-day average and 71.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.